Ulka Vaishampayan, M.D.

University of Michigan Rogel Cancer Center

Co-Leader of the Translational and Clinical Research Program

Director of the Phase 1 Program

University of Michigan, Ann Arbor

Professor of Oncology

Ulka Vaishampayan, MD | Kidney Cancer Research Consortium
Dr. Ulka Vaishampayan is a highly regarded Clinical Professor specializing in Medical Oncology, renowned for her expertise in the treatment of kidney, bladder, and prostate cancers. Dr. Vaishampayan’s career is marked by leadership in early phase clinical trials, translational and clinical research, and a commitment to advancing cancer care through multidisciplinary collaboration.

 

Educational Background:

Dr. Vaishampayan’s journey towards excellence in oncology began at Byramjee Jeejeebhoy Medical School in Pune, India, where she earned her MBBS degree. Her medical education continued at Wayne State University, where she completed her residency and fellowship, solidifying her foundation in medical oncology.

 

Education & Training

Medical School
J. Medical College Pune, 1993
Residency
Wayne State University School of Medicine, Internal Medicine, 1997
Fellowship
Wayne State University School of Medicine, Hematology/Oncology, 2000

 

Professional Organizations:

MSHO Foundation
American Society of Clinical Oncology
Society for Immunotherapy of Cancer
American Association for Cancer Research
SWOG Cancer Research Network

 

Educational and Advisory Roles:

With a formal leadership training course under her belt and recognition as a Fellow of the Advisory Board (FAB), Dr. Vaishampayan’s influence extends beyond patient care and research. Her role as a track leader for the ASCO education committee in the GU non-prostate (Renal and bladder cancer), chair of the SITC membership committee, and chair of the Advanced Renal committee in SWOG track, underscores her commitment to educating and shaping the future of oncology professionals.

She has founded a group called “Women in RCC” with the goal of bridging the gender diversity gap in professional development, with a focus on researchers and clinicians in the field of kidney cancer. She is a grant reviewer for AACR and the Kidney Cancer Association and for the Department of Defense Prostate Cancer panel. She is on the Scientific Advisory Board of KCCure.

Research Contributions:

Dr. Vaishampayan’s research endeavors have been prolific, encompassing translational drug development and the initiation of numerous investigator-initiated trials. Her focus on embedded biomarkers reflects a commitment to advancing personalized medicine in cancer care. Her leadership in obtaining funding for and conducting these trials has established her as a key figure in pushing the boundaries of cancer research.

 

Clinical Expertise:

As the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor, Dr. Vaishampayan has emerged as a leader in translational drug development and early phase clinical trials, particularly in genitourinary malignancies. Her expertise extends to the treatment of kidney, bladder, and prostate cancers, where she has demonstrated clinical excellence and leadership.

 

Leadership & Impact:

Dr. Vaishampayan’s impact extends nationally through her role as the appointed chair of the Advanced Renal Committee of SWOG and as a member of the Renal Task Force of the NCI. Her contributions to the field are further highlighted by her appointment as a board member of the Michigan Society of Hematology/Oncology (MSHO), where she organizes an annual board review course.

In summary, Dr. Ulka Vaishampayan’s multidisciplinary approach, collaborative initiatives, and dedication to education make her an invaluable asset to the University of Michigan’s Rogel Cancer Center and the broader field of oncology.

Naomi Haas, MD | Kidney Cancer Research Consortium

Naomi Haas

UPenn

Daniel George, MD | Kidney Cancer Research Consortium

Daniel George

Duke University

Hans Hammers

UT Southwestern

Eric Jonasch, M.D. | Kidney Cancer Research Consortium

Eric Jonasch

MD Anderson

David McDermott, MD | Kidney Cancer Research Consortium

David McDermott

Beth Israel

Brian Rini, MD | Kidney Cancer Research Consortium

Brian Rini

Vanderbilt University